MedTrace Logo

Mood and Anti-craving Effects of Varenicline in Psychiatric Inpatients

NCT00525928 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2015-07-21

No results posted yet for this study

Summary

This study of psychiatric inpatients will assess mood effects of varenicline, as well as assess if varenicline decreased nicotine cravings acutely.

This study will also measure side effects of varenicline when given in addition to other psychiatric and non-psychiatric medications.

Conditions

  • Smoking
  • Depressive Disorder

Interventions

DRUG

varenicline

varenicline 0.5mg daily for days 1-3, 0.5mg twice daily for days 3-7, then 1mg twice daily for length of hospitalization

Sponsors & Collaborators

  • Brown University

    collaborator OTHER

  • Butler Hospital

    lead OTHER

Principal Investigators

  • Noah S Philip, MD · Butler Hospital

  • Lawrence H Price, MD · Butler Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00525928 on ClinicalTrials.gov